Clever Culture Systems Limited · ASX:CC5
Clever Culture Systems — Investor Presentation (June 2025)
22 slides from Clever Culture Systems's investor presentation, Jun 25, 2025
Slide 1: Updated Company Presentation
Clever Culture Systems Ltd 16 Anster St Adelaide SA 5000 www.cleverculturesystems.com ASX:CC5 UPDATED COMPANY PRESENTATION Adelaide, Australia, 25 June 2025: Leaders in AI microbiology automation, Clever Culture Systems Ltd (ASX: CC5) (CCS or the Company), is pleased to share an updated Company Pres
Slide 2: AI-powered microbiology
ASX: CC5 For personal use only AI-powered microbiology Revolutionising microbial quality control in pharmaceutical manufacturing Brent Barnes, CEO and Managing Director June 2025 Clever Culture Systems ASX: CC5 1
Slide 3: Disclaimer
Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Giv
Slide 4: Technology
Technology APAS® Revolutionising Independence pharma Microbial QC For personal use only Automated reading, interpretation and reporting of testing microbial growth on culture Cutting edge AI technology plates Machine learning for microbiology applications Demonstrated performance Extensive scientifi
Slide 5: Highlights
Highlights ASX: CC5 Market leader • APAS Independence validated culture plate reading technology For personal use only • First and only end-point reader deployed in routine drug manufacturing Growing customer base • 13 instruments sold to pharmaceutical customers since launch in Mar-24 • Early sales
Slide 6: Industry
Industry Environmental Monitoring is a highly regulated process For personal use only • Critical and mandatory process to maintain drug product quality and safety • Measures whether the manufacturing facility is operating in a state of control • Culture plates used for monitoring of air, surfaces, p
Slide 7: Problem
Problem Millions of culture plates are manually Incorrect results costly read and reported annually during pharmaceutical manufacturing High cost of failure Up to US$1bn lost revenue1 For personal use only Failed results in pharmaceutical manufacturing can lead to substantial revenue losses. Catastr
Slide 8: Solution
Solution Digital disruption Solution: APAS Automated Plate Assessment For personal use only System Cutting edge AI technology Machine learning for microbiology applications Demonstrated performance Extensive scientific data, faster than microbiologist Improved data integrity Automatic data trails an
Slide 9: Workflow: Environmental monitoring today
Workflow Environmental monitoring today Mandatory process in every pharmaceutical manufacturing facility globally For personal use only Environmental Culture plates monitoring Critical decision point Culture plate reading, reporting. Result to release pharmaceutical product Cleanrooms No Growth (pha
Slide 10: Workflow: Environmental monitoring with APAS
Workflow Environmental monitoring with APAS Mandatory process in every pharmaceutical manufacturing facility globally For personal use only Environmental Culture plates monitoring Critical decision point Automated culture plate reading No Growth >90% Cleanrooms ➔ Batch release (pharmaceutical manufa
Slide 11: Opportunity
Opportunity AU$2.8B TAM1 Total Addressable Market for aseptic manufacturing microbiology testing. For personal use only Pharma companies are investing in expanding manufacturing facilities and automation 14 of Top 202 Sales pipeline includes largest pharmaceutical manufacturers globally. Opportunity
Slide 12: Market
Market Pharmaceutical manufacturing: Attractive market for optimisation For personal use only Clever Culture Systems. ASX: CC5 11
Slide 13: Revenue
Revenue Up to AU$1.5m revenue per APAS Independence sale1 Includes up-front Capex and Annual Recurring Revenue (ARR) streams For personal use only Approx. Product / Service Description Revenue Model Split APAS® Upfront Capex Laboratory (inc. financing 40% Independence Instrumentation options) APAS A
Slide 14: Competition
Competition Different automation approach APAS Independence: Incubation and reading technologies end point reader • Requires continuous reading between incubator and imaging platform For personal use only • Incubation size restricts volume capacity (60-132 plates per day capacity) APAS delivers scal
Slide 15: Go-to-market strategy
Go-to-market strategy For personal use only Land and expand Land a single instrument sale. APAS expands to become the standard across customer global sites Top-20 largest pharma Focus on the largest biologics manufacturing customers who have many global sites, establishing credibility across industr
Slide 16: AstraZeneca Case Study
Customer AstraZeneca Case Study Enterprise customer – Standardisation across multiple global sites For personal use only 9 instruments purchased • ~1,000 plates per day at large AZ sites and installed • >98% of plates are negative • Occasionally humans make mistakes • Multiple global • APAS resolves
Slide 17: Pipeline: Contact plates launch
Pipeline Contact plates launch: unparalleled advantage Launch Q1 FY26 to accelerate sales pipeline covering major tests For personal use only Settle Plates ~50% used Contact Plates ~50% used Automating more tests in Environmental Monitoring 90mm 55mm Passive and Active Air Sampling, Personnel Monito
Slide 18: APAS Placements
APAS Placements AstraZeneca (7) Pharma Clinical HSL (3) For personal use only AstraZeneca LaDR Albany Medical Centre Limbach Hennepin Labor Dr. Health Wisplinghoff (3) TFS Singapore BMS (2) Quest AstraZeneca Kaiser NovaCina AstraZeneca Evaluation 28 instruments St. Vincent’s installed globally Cleve
Slide 19: Experienced Board and Management
Experienced Board and Management Focused on expansion into pharmaceutical manufacturing industry For personal use only • Board and Management shareholding 20%+ Brent Barnes Rebecca Wilson CEO and MD, AU Chair, AU Aug-16 start Jul-23 start • International experience with healthcare, technology and ph
Slide 20: Financials: Corporate Overview
Financials Corporate Overview Transitioning to profitability Key Statistics (Closing Price on 20 June 2025) Share Price $0.017 per share For personal use only Shares on Issue 1.77 billion 0.025 9 Millions Top-20 Shareholding 65% 8 Market Cap. $30.0 million 0.020 7 ~400 million Listed options (CC5OA)
Slide 21: Snapshot
Snapshot Pharmaceutical sales transition Company Blue-chip customers underpin path to profitability For personal use only Commercial 13 APAS instruments sold Global pharmaceutical customers bought and standardising APAS for to pharma since launch in March environmental monitoring. Substantial market
Slide 22: Outlook
Outlook New sales and placements with Top-20 pharma companies For personal use only Sets established userbase for future sales Growth in customers using the technology in routine operations Drives growth in recurring revenues Contact plate application provides unique value proposition for customers
Clever Culture Systems — Investor Presentation (June 2025) on 6ix